NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma

被引：1
作者：
Tucker, Helen [1 ]
Umeweni, Nwamaka [1 ]
Robertson, Janet [1 ]
Adam, Jane [1 ]
机构：
[1] Natl Inst Hlth & Care Excellence, London SW1A 2BU, England
来源：
LANCET ONCOLOGY | 2014年 / 15卷 / 13期
关键词：
OPEN-LABEL; PHASE-3;
D O I：
10.1016/S1470-2045(14)71033-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1425 / 1426
页数：2
相关论文
共 50 条
  • [41] Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
    Schreuer, Max
    Meersseman, Geert
    Van Den Herrewegen, Sari
    Jansen, Yanina
    Chevolet, Ines
    Bott, Ambre
    Wilgenhof, Sofie
    Seremet, Teofila
    Jacobs, Bart
    Buyl, Ronald
    Maertens, Geert
    Neyns, Bart
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [42] Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
    Atkinson, Victoria
    Sandhu, Shahneen
    Hospers, Geke
    Long, Georgina, V
    Aglietta, Massimo
    Ferrucci, Pier F.
    Tulyte, Skaiste
    Cappellini, Gian Carlo Antonini
    Soriano, Virtudes
    Ali, Sayed
    Poprach, Alexandr
    Cesas, Alvydas
    Rodriguez-Abreu, Delvys
    Lau, Mike
    de Jong, Egbert
    Legenne, Philippe
    Stein, Dara
    King, Brianna
    van Thienen, Johannes, V
    MELANOMA RESEARCH, 2020, 30 (03) : 261 - 267
  • [43] Five- year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma
    Robert, Caroline
    Flaherty, Keith
    Nathan, Paul
    Hersey, Peter
    Garbe, Claus
    Milhem, Mohammed
    Demidov, Lev
    Mohr, Peter
    Hassel, Jessica C.
    Rutkowski, Piotr
    Dummer, Reinhard
    Utikal, Jochen
    Kiecker, Felix
    Larkin, James
    D'Amelio, Anthony, Jr.
    Mookerjee, Bijoyesh
    Schadendorf, Dirk
    EUROPEAN JOURNAL OF CANCER, 2019, 109 : 61 - 69
  • [44] A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting
    Matter-Walstra, K.
    Braun, R.
    Kolb, C.
    Ademi, Z.
    Dummer, R.
    Pestalozzi, B. C.
    Schwenkglenks, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (06) : 1462 - 1470
  • [45] Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
    Chapman, P. B.
    Robert, C.
    Larkin, J.
    Haanen, J. B.
    Ribas, A.
    Hogg, D.
    Hamid, O.
    Ascierto, P. A.
    Testori, A.
    Lorigan, P. C.
    Dummer, R.
    Sosman, J. A.
    Flaherty, K. T.
    Chang, I.
    Coleman, S.
    Caro, I.
    Hauschild, A.
    McArthur, G. A.
    ANNALS OF ONCOLOGY, 2017, 28 (10) : 2581 - 2587
  • [46] Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC
    Planchard, David
    Besse, Benjamin
    Groen, Harry J. M.
    Hashemi, Sayed M. S.
    Mazieres, Julien
    Kim, Tae Min
    Quoix, Elisabeth
    Souquet, Pierre-Jean
    Barlesi, Fabrice
    Baik, Christina
    Villaruz, Liza C.
    Kelly, Ronan J.
    Zhang, Shirong
    Tan, Monique
    Gasal, Eduard
    Santarpia, Libero
    Johnson, Bruce E.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (01) : 103 - 115
  • [47] Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma A Pooled Analysis of 4 Clinical Trials
    Larkin, James
    Lao, Christopher D.
    Urba, Walter J.
    McDermott, David F.
    Horak, Christine
    Jiang, Joel
    Wolchok, Jedd D.
    JAMA ONCOLOGY, 2015, 1 (04) : 433 - 440
  • [48] BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases
    Xu, Zhiyuan
    Lee, Cheng-Chia
    Ramesh, Arjun
    Mueller, Adam C.
    Schlesinger, David
    Cohen-Inbar, Or
    Shih, Han-Hsun
    Sheehan, Jason P.
    JOURNAL OF NEUROSURGERY, 2017, 126 (03) : 726 - 734
  • [49] NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer
    Dillon, Bernice
    Naidoo, Bhash
    Knight, Helen
    Clark, Peter
    LANCET ONCOLOGY, 2012, 13 (08) : 764 - 765
  • [50] Discordance Between Cobas BRAF V600 Testing and VE1 Immunohistochemistry in a Melanoma Patient With Bone Marrow Metastases
    Rapisuwon, Suthee
    Busam, Klaus J.
    Parks, Kellie
    Chapman, Paul B.
    Lee, Elsie
    Atkins, Michael B.
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2016, 38 (09) : 687 - 689
12345